세계의 소아 특발성 관절염 치료 시장(2025-2035년)

Juvenile Idiopathic Arthritis Treatment Market Size, Share & Trends Analysis Report by Type (Systemic JIA (Still's Disease), Oligoarticular JIA, Polyarticular JIA (Rheumatoid Factor Positive and Negative), Psoriatic Arthritis, Enthesitis-Related Arthritis and Undifferentiated Arthritis), by Route of Administration (Oral, Injectable, and Topical), and by Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Corticosteroids and Other Medications) Forecast Period (2025-2035)

Industry Overview

Juvenile idiopathic arthritis treatment market was valued at $3.0 billion in 2023 and is projected to reach $5.8 billion by 2035, growing at a CAGR of 6.1% during the forecast period (2025-2035). The JIA therapeutic industry growth is driven by the high prevalence of juvenile idiopathic arthritis, the growing adoption of innovative drug delivery technologies, and the growing integration of clinical trials with pediatric rheumatology research with a rising emphasis on customized care. According to the Arthritis Foundation, 3 million children and young adults are estimated to be affected by Juvenile idiopathic arthritis, the most prevalent type of pediatric rheumatic disease.

Market Dynamics

Increasing Focus on Early Diagnosis and Multidisciplinary Care

The market trend is changing as multidisciplinary care and early diagnosis growing more widely used. Regular intervention has grown increasingly vital to prevent irreparable joint damage and improve overall long-term results. Pediatric rheumatologists and occupational therapists collaborate to create complete care programs that are tailored to each child's needs. Additionally, increasing advancements in diagnostic methods such as biomarkers and imaging technology are being made to help children with JIA live better lives. Healthcare companies incorporate telemedicine services to enable regular follow-ups and remove obstacles to expert care. The Arthritis Foundation and its partners have designated July as Juvenile Arthritis (JA) Awareness Month to raise awareness about juvenile arthritis and other childhood rheumatic diseases. Foundation partners include the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Childhood Arthritis Rheumatology Research Alliance (CARRA), Alpha Omicron Pi (AOII), and countless other organizations and individuals.

Growing Expansion of Biologic Therapies

Biologic therapies are increasingly common for the treatment of juvenile idiopathic arthritis. Advanced medications including interleukin and tumor necrosis factor inhibitors are gaining acceptance to target particular immune pathways responsible for inflammation. Biologics offer more individualized care than conventional medications such as methotrexate or NSAIDs, to reduce the risk of long-term joint injury in young patients. Growing research in biosimilars results in increasing cost-effectiveness and access to these treatments. The increasing acceptance of biological drugs intended for use in children. For moderate to severe instances, doctors are increasingly recommending biologics to improve symptom management. The growing awareness of these medicines' efficacy among caregivers is contributing to their acceptability. Regulatory authorization in certain places has accelerated their integration into therapeutic approaches. This trend reflects the broader shift toward precision medicine in the management of autoimmune diseases.

Market Segmentation

• Based on the type, the market is segmented into systemic JIA (still's disease), oligoarticular JIA, polyarticular JIA (rheumatoid factor positive and negative), psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis.
• Based on the route of administration, the market is segmented into oral, injectable, and topical.
• Based on the drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, and other medications (biologic agents).

Know More About JIA Types and Symptoms

Systemic arthritis typically has symptoms such as spiking fever, rash, and arthritis, with about a quarter of children potentially developing severe destructive disease. Oligoarthritis involves up to four joints within the first six months and can either remain persistent (affecting no more than four joints) or become extended (affecting more than four joints after six months); it is often associated with uveitis. Rheumatoid-factor positive (RF+) polyarthritis affects five or more joints within the first six months and is more likely to lead to destructive joint disease, with a possible association with uveitis. Similarly, rheumatoid-factor negative (RF-) polyarthritis also involves five or more joints within the first six months and may be linked to uveitis. Enthesitis-related arthritis and psoriatic arthritis may both be associated with uveitis. Lastly, undifferentiated arthritis refers to cases lasting more than six weeks that either do not meet the criteria for any specific category or fulfill criteria for multiple categories.

Psoriatic Arthritis Segment to Lead the Market with the Largest Share

Growing advancements in psoriatic arthritis treatments with innovative biologics and disease-modifying antirheumatic drugs, that are crucial for symptom control and improving patient outcomes, are the main growth drivers. To continue to expand the availability of effective pharmaceuticals globally, more funds are being allocated to research and development in response to the growing demand for specific therapies to treat psoriatic arthritis in young people. For instance, in May 2024, Boehringer Ingelheim announced that the US FDA has authorized the citrate-free, high-concentration version of Cyltezo(R) (adalimumab-adbm) for the treatment of many chronic inflammatory conditions. Cyltezo is used to treat psoriatic arthritis (PsA) in adults and moderate to severe polyarticular JIA in children aged 2 and up. Methotrexate and CYLTEZO can be taken together or separately.

Injectable: A Key Segment in Market Growth

The factors supporting segment growth include the increasing innovation in treatments involving injections, by reducing inflammation and improving joint function, such therapies offer focused relief. Injectable medications are growing increasingly common among doctors owing to their rapid action and sustained efficacy. Injectable biologic drugs play a crucial role in the management of severe JIA. For instance, in June 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US FDA has approved Kevzara(R) (sarilumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA), a type of arthritis that affects numerous joints at once. KEVZARA(R) is a prescription injectable medication that blocks the interleukin-6 (IL-6) receptor. KEVZARA is used to treat active polyarticular juvenile idiopathic arthritis (pJIA) and polymyalgia rheumatica (PMR).

Regional Outlook

The global juvenile idiopathic arthritis treatment market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America)

Growing Investment in Research and Development in Europe

The market for JIA treatments in Europe is expected to rise significantly owing to developments in biologic therapy with a rising incidence of juvenile idiopathic arthritis, the launch of biosimilars, and higher R&D spending. According to the Journal of Health Economics and Outcomes Research (JHEOR), in December 2023, JIA is the most frequent chronic rheumatic disease in children, with an annual incidence of 2 to 20 per 100 000 children and a prevalence in Europe of 16.9 to 167 per 100 000. Pharmaceutical companies are constantly funding research and development to find more effective treatments for JIA. The growth of collaborations between research centers and medical institutions is another element driving progress.

North America Region Dominates the Market with Major Share

North America holds a significant share owing to the presence of juvenile idiopathic arthritis treatment offering companies such as AbbVie Inc., Amgen Inc., Eli Lilly and Co., Johnson & Johnson Services, Inc., Pfizer Inc., and others. According to the Centers for Disease Control and Prevention (CDC) (in July 2023), the prevalence of JIA is most common between the ages of 12 and 17 in 2017-2021. In the US 220,000 children and adolescents in the US were diagnosed with arthritis. Early diagnosis, increased treatment choices owing to increased awareness, and a rise in pediatric JIA patients all contributed to the market's expansion. The major companies provide a high-concentration, citrate-free formulation for the treatment of juvenile idiopathic arthritis. For instance, in August 2024, Celltrion USA, Inc. announced that FDA-approved biosimilar adalimumab-aaty. Adalimumab-Aaty is a citrate-free biosimilar of Humira(R) (adalimumab) that is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and Hidradenitis Suppurativa. It has a high concentration (100 mg/mL).

Market Players Outlook

The major companies operating in the global juvenile idiopathic arthritis treatment market include Bristol Myers Squibb Co. (BMS), Eli Lilly and Co., Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In February 2024, Alvotech and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. announced that the US (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an equivalent biosimilar to Humira, SIMLANDI (adalimumab-ryvk) injection has been approved by the US (FDA) to treat adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.
• In January 2023, Samsung Bioepis Co., Ltd. announced that HADLIMATM (also called SB5), a citrate-free, high concentration (40 mg/0.4 ML) biosimilar formulation referencing HUMIRA(R) (adalimumab), has been approved by Health Canada. Adult Crohn's disease, ulcerative colitis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis (RA), adult and adolescent hidradenitis suppurativa, plaque psoriasis, and adult and pediatric uveitis are among the conditions for which HADILMA is prescribed.

The Report Covers:

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global juvenile idiopathic arthritis treatment market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration | Drug Class ($ Million)
• Juvenile Idiopathic Arthritis Treatment Market Sales Performance of Top Countries
• 1.1. Research Methodology
• Primary Research Approach
• Secondary Research Approach
• 1.2. Market Snapshot

2. Market Overview and Insights

• 2.1. Scope of the Study
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Juvenile Idiopathic Arthritis Treatment Industry Trends
  • 2.2.2. Market Recommendations
• 2.3. Porter's Five Forces Analysis for the Juvenile Idiopathic Arthritis Treatment Market
  • 2.3.1. Competitive Rivalry
  • 2.3.2. Threat of New Entrants
  • 2.3.3. Bargaining Power of Suppliers
  • 2.3.4. Bargaining Power of Buyers
  • 2.3.5. Threat of Substitutes

3. Market Determinants

• 3.1. Market Drivers
  • 3.1.1. Drivers For Global Juvenile Idiopathic Arthritis Treatment Market: Impact Analysis
• 3.2. Market Pain Points and Challenges
  • 3.2.1. Restraints For Global Juvenile Idiopathic Arthritis Treatment Market: Impact Analysis
• 3.3. Market Opportunities

4. Competitive Landscape

• 4.1. Competitive Dashboard - Juvenile Idiopathic Arthritis Treatment Market Revenue and Share by Manufacturers
• 4.2. Key Company Analysis
  • 4.2.1. Bristol Myers Squibb Co. (BMS)
    • 4.2.1.1. Overview
    • 4.2.1.2. Product Portfolio
    • 4.2.1.3. Financial Analysis (Subject to Data Availability)
    • 4.2.1.4. SWOT Analysis
    • 4.2.1.5. Business Strategy
  • 4.2.2. Eli Lilly and Co.
    • 4.2.2.1. Overview
    • 4.2.2.2. Product Portfolio
    • 4.2.2.3. Financial Analysis (Subject to Data Availability)
    • 4.2.2.4. SWOT Analysis
    • 4.2.2.5. Business Strategy
  • 4.2.3. Hoffmann-La Roche AG
    • 4.2.3.1. Overview
    • 4.2.3.2. Product Portfolio
    • 4.2.3.3. Financial Analysis (Subject to Data Availability)
    • 4.2.3.4. SWOT Analysis
    • 4.2.3.5. Business Strategy
  • 4.2.4. Johnson & Johnson Services, Inc.
    • 4.2.4.1. Overview
    • 4.2.4.2. Product Portfolio
    • 4.2.4.3. Financial Analysis (Subject to Data Availability)
    • 4.2.4.4. SWOT Analysis
    • 4.2.4.5. Business Strategy
  • 4.2.5. Pfizer Inc.
    • 4.2.5.1. Overview
    • 4.2.5.2. Product Portfolio
    • 4.2.5.3. Financial Analysis (Subject to Data Availability)
    • 4.2.5.4. SWOT Analysis
    • 4.2.5.5. Business Strategy
• 4.3. Top Winning Strategies by Market Players
  • 4.3.1. Merger and Acquisition
  • 4.3.2. Product Launch
  • 4.3.3. Partnership And Collaboration

5. Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis by Type ($ Million)

• 5.1. Systemic JIA (Still's Disease)
• 5.2. Oligoarticular JIA
• 5.3. Polyarticular JIA (Rheumatoid Factor Positive and Negative)
• 5.4. Psoriatic Arthritis
• 5.5. Enthesitis-Related Arthritis
• 5.6. Undifferentiated Arthritis

6. Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis by Route of Administration ($ Million)

• 6.1. Oral
• 6.2. Injectable
• 6.3. Topical

7. Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis by Drug Class ($ Million)

• 7.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• 7.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• 7.3. Corticosteroids
• 7.4. Other Medications (Biologic Agents)

8. Regional Analysis

• 8.1. North American Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for North America
  • 8.1.1. United States
  • 8.1.2. Canada
• 8.2. European Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for Europe
  • 8.2.1. UK
  • 8.2.2. Germany
  • 8.2.3. Italy
  • 8.2.4. Spain
  • 8.2.5. France
  • 8.2.6. Russia
  • 8.2.7. Rest of Europe
• 8.3. Asia-Pacific Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for Asia-Pacific
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
  • 8.3.4. India
  • 8.3.5. Australia & New Zealand
  • 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
  • 8.3.7. Rest of Asia-Pacific
• 8.4. Rest of the World Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for the Rest of the World
  • 8.4.1. Latin America
  • 8.4.2. Middle East and Africa

9. Company Profiles

• 9.1. AbbVie Inc.
  • 9.1.1. Quick Facts
  • 9.1.2. Company Overview
  • 9.1.3. Product Portfolio
  • 9.1.4. Business Strategies
• 9.2. Amgen Inc.
  • 9.2.1. Quick Facts
  • 9.2.2. Company Overview
  • 9.2.3. Product Portfolio
  • 9.2.4. Business Strategies
• 9.3. Biogen Inc.
  • 9.3.1. Quick Facts
  • 9.3.2. Company Overview
  • 9.3.3. Product Portfolio
  • 9.3.4. Business Strategies
• 9.4. Bio-Thera Solutions, Ltd.
  • 9.4.1. Quick Facts
  • 9.4.2. Company Overview
  • 9.4.3. Product Portfolio
  • 9.4.4. Business Strategies
• 9.5. Bristol Myers Squibb Co. (BMS)
  • 9.5.1. Quick Facts
  • 9.5.2. Company Overview
  • 9.5.3. Product Portfolio
  • 9.5.4. Business Strategies
• 9.6. CELLTRION INC.
  • 9.6.1. Quick Facts
  • 9.6.2. Company Overview
  • 9.6.3. Product Portfolio
  • 9.6.4. Business Strategies
• 9.7. Chugai Pharmaceutical Co., Ltd.
  • 9.7.1. Quick Facts
  • 9.7.2. Company Overview
  • 9.7.3. Product Portfolio
  • 9.7.4. Business Strategies
• 9.8. Cumberland Pharmaceuticals Inc.
  • 9.8.1. Quick Facts
  • 9.8.2. Company Overview
  • 9.8.3. Product Portfolio
  • 9.8.4. Business Strategies
• 9.9. Eli Lilly and Co.
  • 9.9.1. Quick Facts
  • 9.9.2. Company Overview
  • 9.9.3. Product Portfolio
  • 9.9.4. Business Strategies
• 9.10. Fresenius SE & Co. KGaA
  • 9.10.1. Quick Facts
  • 9.10.2. Company Overview
  • 9.10.3. Product Portfolio
  • 9.10.4. Business Strategies
• 9.11. Genentech, Inc.
  • 9.11.1. Quick Facts
  • 9.11.2. Company Overview
  • 9.11.3. Product Portfolio
  • 9.11.4. Business Strategies
• 9.12. Hoffmann-La Roche AG
  • 9.12.1. Quick Facts
  • 9.12.2. Company Overview
  • 9.12.3. Product Portfolio
  • 9.12.4. Business Strategies
• 9.13. Johnson & Johnson Services, Inc.
  • 9.13.1. Quick Facts
  • 9.13.2. Company Overview
  • 9.13.3. Product Portfolio
  • 9.13.4. Business Strategies
• 9.14. Laboratorios Gebro Pharma, SA
  • 9.14.1. Quick Facts
  • 9.14.2. Company Overview
  • 9.14.3. Product Portfolio
  • 9.14.4. Business Strategies
• 9.15. Mylan N.V.
  • 9.15.1. Quick Facts
  • 9.15.2. Company Overview
  • 9.15.3. Product Portfolio
  • 9.15.4. Business Strategies
• 9.16. Novartis International AG
  • 9.16.1. Quick Facts
  • 9.16.2. Company Overview
  • 9.16.3. Product Portfolio
  • 9.16.4. Business Strategies
• 9.17. Ono Pharmaceutical Co., Ltd.
  • 9.17.1. Quick Facts
  • 9.17.2. Company Overview
  • 9.17.3. Product Portfolio
  • 9.17.4. Business Strategies
• 9.18. Organon & Co.
  • 9.18.1. Quick Facts
  • 9.18.2. Company Overview
  • 9.18.3. Product Portfolio
  • 9.18.4. Business Strategies
• 9.19. Pfizer Inc.
  • 9.19.1. Quick Facts
  • 9.19.2. Company Overview
  • 9.19.3. Product Portfolio
  • 9.19.4. Business Strategies
• 9.20. Regeneron Pharmaceuticals, Inc.
  • 9.20.1. Quick Facts
  • 9.20.2. Company Overview
  • 9.20.3. Product Portfolio
  • 9.20.4. Business Strategies
• 9.21. Rosemont Pharmaceuticals Ltd.
  • 9.21.1. Quick Facts
  • 9.21.2. Company Overview
  • 9.21.3. Product Portfolio
  • 9.21.4. Business Strategies
• 9.22. Samsung Bioepis Co., Ltd.
  • 9.22.1. Quick Facts
  • 9.22.2. Company Overview
  • 9.22.3. Product Portfolio
  • 9.22.4. Business Strategies
• 9.23. Sanofi S.A.
  • 9.23.1. Quick Facts
  • 9.23.2. Company Overview
  • 9.23.3. Product Portfolio
  • 9.23.4. Business Strategies
• 9.24. Shanghai Henlius Biotech, Inc.
  • 9.24.1. Quick Facts
  • 9.24.2. Company Overview
  • 9.24.3. Product Portfolio
  • 9.24.4. Business Strategies
• 9.25. Swedish Orphan Biovitrum AB ("Sobi")
  • 9.25.1. Quick Facts
  • 9.25.2. Company Overview
  • 9.25.3. Product Portfolio
  • 9.25.4. Business Strategies
• 9.26. Teva Pharmaceutical Industries Ltd.
  • 9.26.1. Quick Facts
  • 9.26.2. Company Overview
  • 9.26.3. Product Portfolio
  • 9.26.4. Business Strategies
• 9.27. Therakind Ltd.